Xuesaitong Soft Capsule (Chinese Patent Medicine) for the Treatment of Unstable Angina Pectoris: A Meta-Analysis and Systematic Review

Table 1

The characteristics of included RCTs of Xuesaitong soft capsule for UA.

Study ID	Sample (T/C)	Diagnosis standard	Age	Intervention group	Control group	Course (week)	Outcome measures
Xiong et al., 2006 [13]	89/79	1979; ISFC/WHO	37–68	XST + conventional drugs	Conventional drugs	8	FAA, and DAA
Du and Chen, 2009 [14]	56/56	2002; ACCF/AHA	58.8±9.2	XST + conventional drugs	Conventional drugs	4	FAA, DAA, and adverse event
Yu, 2010 [15]	50/50	2002; ACCF/AHA	64.18±12.13	XST + conventional drugs	Conventional drugs	4	RAS, ECG, adverse event, and Followup
Ge and Zhao, 2010 [16]	48/48	1979; ISFC/WHO	53±2	XST + conventional drugs	Conventional drugs	4	RAS, ECG, and adverse event
Kong and Zhang, 2006 [17]	30/30	1979; ISFC/WHO	36–77	XST + conventional drugs	Conventional drugs	4	RAS, ECG, and FAA
Wei, 2010 [18]	90/90	1979; ISFC/WHO	60.4±3.5	XST + conventional drugs	Conventional drugs	4	RAS, ECG, FAA, DAA, and adverse event

T/C: treatment group/control group; XST: Xuesaitong soft capsule; RAS: reduction of angina symptoms; FAA: frequency of angina attack; DAA: duration of angina attack.